Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Coeptis Therapeutics Holdings (COEP) has issued an announcement.
The Company’s Compensation Committee and Board of Directors have approved a significant incentive for CEO David Mehalick, awarding him options to acquire 2.4 million shares at the closing price on the date of approval, vested immediately with a 10-year term. Additionally, the firm announced the successful closure of their Series A Preferred sale in a recent press release.
See more data about COEP stock on TipRanks’ Stock Analysis page.